Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | FHIT | P49789 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28793318 | 0.98 | TDP1 (0.56) | TDP1ALDH1A1CYP1A2MEN1KMT2A | |
| SCHEMBL13468179 | 0.82 | KDM4E (0.44) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL13469118 | 0.81 | KDM4E (0.43) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL4703254 | 0.81 | CA12 (0.46) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL16571310 | 0.79 | HSD17B2 (0.44) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL9369833 | 0.79 | TDP1 (0.61) | TDP1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL15614506 | 0.77 | KDM4E (0.40) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL9632139 | 0.75 | TSHR (0.46) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL3868869 | 0.71 | TSHR (0.50) | ALDH1A1CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL2843820 | 0.71 | ALDH1A1 (0.59) | ALDH1A1CYP1A2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-3523305-B1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-25 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| WO-2018067432-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNAR1 | TDP1 1506/4885ALDH1A1 3821/4885CYP1A2 692/4885 |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-10570145-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TDP1 330/4885ALDH1A1 4827/4885CYP1A2 3935/4885 |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | TYK2, IL2, IFNAR1 | TDP1 2207/4885ALDH1A1 3818/4885CYP1A2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.